RESEARCH PROTOCOL

AOD-9604: Dosage, Calculator & Reconstitution Guide

Modified GH fragment (hGH 176-191) studied for lipolysis — research context only.

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic modified fragment corresponding to the C-terminal region of human growth hormone — residues 176-191 of the 191-amino-acid hGH molecule, with an added disulfide bridge. It was originally developed in the 1990s at Monash University as an anti-obesity candidate and later advanced through clinical development by Metabolic Pharmaceuticals.

The proposed mechanism links AOD-9604 to beta-3 adrenergic receptor activation, which in preclinical models is associated with increased lipolysis (breakdown of stored fat) and decreased lipogenesis (formation of new fat). Because it lacks the receptor-binding regions of full-length GH, it is not expected to produce the growth-promoting, IGF-1-raising, or blood-sugar effects associated with exogenous GH administration.

AOD-9604 completed six placebo-controlled clinical trials with over 900 combined participants. Development for the obesity indication was discontinued in 2007 after the largest Phase IIb trial failed to show statistically significant weight loss versus placebo at the primary endpoint. The FDA's 2024 review of AOD-9604 states that the precise mechanism of action remains unconfirmed.

This is a research-summary page. AOD-9604 is not FDA-approved as a therapeutic drug. Nothing here constitutes a health claim or medical recommendation.

Common Research Doses

Typical vial sizeBAC water volumeCommon dose rangeTypical frequency
5 mg2 mL300–500 mcgDaily, morning, fasted
10 mg2 mL300–500 mcgDaily, morning, fasted

AOD-9604 is dosed in micrograms (mcg). Research protocols typically administer once daily in the morning on an empty stomach.

Reconstitution Reference

Reconstitution is the process of dissolving lyophilized peptide powder in bacteriostatic water. Add BAC water slowly down the side of the vial, swirl gently until fully dissolved, and do not shake. Once reconstituted, store refrigerated.

AOD-9604 is commonly administered on an empty stomach, with users often waiting 30–60 minutes before eating. The rationale in research protocols is that circulating free fatty acids and insulin can blunt lipolytic signaling.

Vial sizeBAC waterConcentrationDoses at 300 mcgDoses at 500 mcg
5 mg2.0 mL2.5 mg/mL (2500 mcg/mL)85
10 mg2.0 mL5.0 mg/mL (5000 mcg/mL)1610

Compare all peptides on the Peptide Dosage Chart.

Calculate your exact syringe draw

Calculate Your AOD-9604 Dose →

Storage & Stability

ItemStateRecommendation
Lyophilized vialSealed powder, unopenedStore at -20°C long-term; refrigerate for short-term
Reconstituted vialIn BAC water solutionRefrigerate at 2–8°C; use within 14–28 days
Bacteriostatic waterMulti-use vialRoom temperature; discard 28 days after first puncture
Light exposureAny formProtect from direct light; store in original box

Sourcing

Recommended Supplier

PSPeptides carries third-party tested, research-grade AOD-9604 with published COAs.

Discount Code: BANANAS10

Website: pspeptides.com/?ref=bananas

Shop PSPeptides →

Affiliate disclosure: The Protocol Kit earns a commission from qualifying purchases at no additional cost to you.

Related metabolic-adjacent compounds: Tesamorelin · MOTS-c

Frequently Asked Questions

Disclaimer: The information on this page is provided for research and educational purposes only. AOD-9604 is not FDA-approved as a therapeutic drug; development for the obesity indication was discontinued in 2007. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before making any health-related decisions.